[Federal Register Volume 72, Number 57 (Monday, March 26, 2007)]
[Notices]
[Pages 14124-14125]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-5426]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Rapid Universal and/or Type-Specific Assay for Clostridium Botulinum
Description of Technology: The urgent need for a rapid diagnostic
test capable of detecting all serotypes of C. botulinum is well known.
Botulinum neurotoxins (BoNTs) are the most potent biological toxins
known and are categorized as category A biodefense agents because of
lethality and ease of production. Current diagnostic methods include
clinical observation of symptoms that could be mistaken for other
neurological conditions and a mouse protection bioassay that takes as
long as four days and has a number of disadvantages. The subject
technology utilizes unique PCR primers for the detection of the non-
toxin non-hemaglutinin (NTNH) gene of C. botulinum; this gene is highly
conserved in all C. botulinum toxin types and subtypes. Thus, samples
that contain botulinum can be determined regardless of serotype
involved, providing a universal means of diagnosis. Further, the
technology describes different PCR primers and flurogenic probes for a
BoNT-specific assay. The type-specific assay can be used independently
or in conjunction with the universal assay described above. The
universal and type-specific assays were successfully used first to
[[Page 14125]]
identify positively botulinum DNA samples in a test of botulinum and
non-botulinum clostridia species then to determine the toxin type. The
diagnostic testing described by the subject technology requires
significantly less time than the current gold standard diagnostic test.
Applications: (1) Universal diagnostic test for C. botulinum; (2)
Diagnostic test for C. botulinum capable of detecting all seven toxin
types; (3) Combination diagnostic.
Development Status: Fully developed.
Inventors: Daniel C. Douek (VRC/NIAID) et al.
Patent Status: U.S. Provisional Application No. 60/884,539 filed 11
Jan 2007 (HHS Reference No. E-046-2007/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Susan Ano, Ph.D.; 301/435-5515;
[email protected].
Methods and Compositions for Protecting Cells From Ultrasound-Mediated
Cytolysis
Description of Invention: Available for licensing and commercial
development are methods for protecting cells from ultrasound-mediated
cytolysis. The in vitro exposure of cells to ultrasound and the
therapeutic uses of ultrasound (e.g., sonoporation, thrombolysis, HIFU,
sonophoresis, acoustic hemostasis) may induce changes in tissue state,
including apoptosis and cytolysis, through thermal effects (e.g.,
hyperthermia), mechanical effects (e.g., acoustic cavitation or through
radiation force, acoustic streaming and other ultrasound induced
forces), and chemical effects (via sonochemistry or by the activation
of solutes by sonoluminescence). Ultrasound exposure conditions in
these biomedical and in biological processes (e.g. ultrasound
bioreactors) are limited by the need to increase the beneficial effects
of ultrasound, while at the same time limiting the detrimental effects,
such as apoptosis and cytolysis. Accordingly, the protecting molecules
used to carry out the methods of the invention possess the ability to
protect cells against ultrasound mediated cytolysis, without hindering
ultrasound induced physical effects that could be utilized to create
beneficial effects. The protecting solutes are surface active and
possess at least one ``carbohydrate unit'' as described. The solutes
include, but are not limited to: alkyl-[beta]-D-thioglucopyranoside,
alkyl-[beta]-D-thiomaltopyranoside, alkyl-[beta]-D-galactopyranoside,
alkyl-[beta]-D-thiogalactopyranoside, or alkyl-[beta]-D-maltrioside,
hexyl-[beta]-D-glucopyranoside, heptyl-[beta]-D-glucopyranoside, octyl-
[beta]-D-glucopyranoside, nonyl-[beta]-D-glucopyranoside, hexyl-[beta]-
D-maltopyranoside, n-octyl-[beta]-D-maltopyranoside, n-octyl-[beta]-D-
thioglucopyranoside, 2-propyl-1-pentyl-[beta]-D-maltopyranoside,
methyl-6-O-(N-heptylcarbamoyl)-[alpha]-D-glucopyranoside, 3-cyclohexyl-
1-propyl-[beta]-D-glucoside, 6-O-methyl-n-heptylcarboxyl-[alpha]-D-
glucopyranoside.
Inventors: Joe Z. Sostaric (NCI), Peter Riesz (NCI), et al.
Publications:
1. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. DeGraff
and James B. Mitchell. n-Alkyl glucopyranosides completely inhibit
ultrasound-induced cytolysis. Free Radic Biol Med. 2005 Dec
15;39(12):1539-1548.
2. Joe Z. Sostaric, Norio Miyoshi, Peter Riesz, William G. Degraff
and James B. Mitchell. Complete inhibition of ultrasound-induced
cytolysis in the presence of inertial cavitation. AIP Conf Proc. 2006
May 8;829:39-43.
Patent Status: PCT Application No. PCT/US2005/037912 filed 19 Oct
2005, which published as WO 2006/045050 on 27 Apr 2006; claiming
priority to 19 Oct 2004 (HHS Reference No. E-311-2004/0-PCT-02).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Michael Shmilovich, Esq.; 301/435-5019;
[email protected].
Dated: March 12, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-5426 Filed 3-23-07; 8:45 am]
BILLING CODE 4140-01-P